GlassScriptPhysician profile
Jason A Watt
NPI 1487821641
$1,902.73
in general payments reported to CMS, 2019-2025
28 companies · $307 in 2025
The $307 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $101 · 2020: $49.33 · 2021: $224 · 2022: $354 · 2023: $462 · 2024: $407 · 2025: $307.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,175.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $383.14 | 2021-2024 | Mavyret, Qulipta, Vraylar |
| Indivior INC. | $218.71 | 2019-2023 | Sublocade |
| Neurocrine Biosciences, INC. | $213.83 | 2022-2025 | Ingrezza |
| Novo Nordisk INC | $202.59 | 2020-2023 | |
| Gilead Sciences, INC. | $114.67 | 2021-2023 | |
| Lundbeck LLC | $74.83 | 2023-2025 | Rexulti |
| Amgen INC. | $64.81 | 2024-2025 | Otezla, Repatha, Repatha |
| Xeris Pharmaceuticals, INC. | $61.60 | 2021-2022 | |
| Glaxosmithkline, LLC. | $60.58 | 2025 | Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $53.07 | 2024 | Airsupra, Farxiga |
| Lilly USA, LLC | $49.69 | 2023-2025 | Mounjaro, Zepbound |
| Mylan Specialty L.P. | $44.97 | 2023 | Yupelri |
| Otsuka America Pharmaceutical, INC. | $44.41 | 2024 | Rexulti |
| Sk Life Science, INC. | $33.40 | 2025 | |
| Alkermes, INC. | $26.03 | 2019-2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $24.66 | 2025 | Caplyta |
| Noven Therapeutics, LLC | $23.35 | 2025 | Secuado |
| Viatris Specialty LLC | $22.10 | 2025 | Yupelri |
| Sun Pharmaceutical Industries INC. | $21.98 | 2021 | |
| Janssen Pharmaceuticals, INC | $21.50 | 2024 | Spravato |
| Idorsia Pharmaceuticals US INC | $21.46 | 2023 | Quviviq |
| Braeburn INC. | $21.28 | 2023 | Brixadi |
| Abbott Laboratories | $20.11 | 2024 | Freestyle Libre 3 |
| Teva Pharmaceuticals USA, INC. | $18.78 | 2025 | Austedo Xr |
| Ultragenyx Pharmaceutical INC. | $17.47 | 2022 | |
| Avanir Pharmaceuticals, INC. | $16.07 | 2021 | |
| Orexo US, INC. | $14.04 | 2020 | |
| Cipher Pharmaceuticals US LLC | $13.60 | 2025 | Spinosad, Natroba |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Watt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.